INSMED INC (INSM) 21.69 +0.23 (+1.07%)
21.69 +0.23 (+1.07%)
US4576693075 - Common Stock - After market: 21.69 0 (0%)
Buy % Consensus
Analysts have set a mean price target of 41.43. This target is 91% above the current price.
INSM was analyzed by 19 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about INSM.
In the previous month the buy percentage consensus was at a similar level.
INSM was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target
Up and Down Grades
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-01-20 | Barclays | Maintains | Overweight |
| 2023-01-09 | Goldman Sachs | Maintains | Buy |
| 2022-12-09 | Mizuho | Initiate | Buy |
| 2022-12-08 | Barclays | Initiate | Overweight |
| 2022-12-07 | Barclays | Initiate | Overweight |
| 2022-11-18 | B of A Securities | Initiate | Buy |
| 2022-10-27 | SVB Leerink | Maintains | Outperform |
| 2022-10-25 | Cantor Fitzgerald | Maintains | Overweight |
| 2022-10-21 | Cowen & Co. | Maintains | Outperform |
| 2022-07-15 | Morgan Stanley | Maintains | Overweight |
| 2022-05-24 | Goldman Sachs | Maintains | Buy |
| 2022-04-27 | Goldman Sachs | Initiate | Buy |
| 2022-02-22 | SVB Leerink | Maintains | Outperform |
| 2021-12-06 | JP Morgan | Initiate | Overweight |
| 2021-10-08 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-05-10 | Morgan Stanley | Maintains | Overweight |
| 2021-03-02 | Morgan Stanley | Maintains | Overweight |
Analyst Ratings Stock Screener Links
Best Analyst Rating Competitors Stock Screener
Find the competitors with the best analyst ratings on the USA